Abeona Therapeutics Inc
LSE:0H7R
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Abeona Therapeutics Inc
LSE:0H7R
|
US |
|
D
|
Datagroup SE
XETRA:D6H
|
DE |
|
B
|
Bayzed Health Group Inc
HKEX:2609
|
CN |
Abeona Therapeutics Inc
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in New York City, New York and currently employs 90 full-time employees. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in New York City, New York and currently employs 90 full-time employees. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.
Launch momentum: ZEVASKYN commercial launch resumed—2 patients treated since Q4 2025, 1 treated this quarter, 3 additional patients biopsied with more biopsies expected soon.
QTC footprint: Four qualified treatment centers (QTCs) are activated (2 treating, 2 in administrative/onboarding stages); company is working to onboard 5 more and aims for at least 7 QTCs by end of 2026.
Demand growth: Identified eligible patient pool expanded from ~50 to more than 100 after field team deployment; ~10 patients are advancing through administrative steps targeting Q2 2026 biopsies.
Payer coverage: Major commercial payers (UnitedHealthcare, Cigna, Aetna, Anthem and most BCBS plans) cover ZEVASKYN (~80% commercially covered lives); Medicaid baseline coverage across all 50 states and a permanent HCPCS J-code effective Jan 1, 2026.
Manufacturing capacity: Current facility cadence is 6 patients/month with a planned ramp to 10 patients/month later this year; manufacturing lead time is ~25 days per patient.
Financials snapshot: 2025 total revenue $5.8M (includes $2.4M net product revenue from the first commercial treatment and $3.4M license/other), net income $71.2M driven largely by a $152.4M gain from sale of a rare pediatric disease voucher; cash and short-term investments $191.4M as of 12/31/2025.
Profitability trigger: Management stated that roughly >3 patients/month (3.5+ mentioned) would move the company toward profitability versus an annual company burn around $100 million.
